human
parvoviru
nonenvelop
icosahedr
viru
singlestrand
dna
genom
classifi
within
erythroviru
genu
parvovirida
famili
viru
readili
transmit
via
respiratori
rout
worldwid
distribut
seropreval
increas
age
adult
detect
antibodi
sinc
discoveri
associ
expand
rang
clinic
disord
reflect
patient
immunolog
hematolog
statu
healthi
individu
typic
caus
mild
childhood
febril
ill
known
erythema
infectiosum
fifth
diseas
sever
manifest
infect
arthropathi
aplast
anemia
hydrop
fetali
fetal
death
viremia
occur
first
week
infect
viru
predilect
bone
marrow
erythroid
progenitor
cell
height
viremia
abrupt
fall
reticulocyt
count
anemia
superven
although
rare
appar
healthi
patient
seriou
clinic
consequ
preexist
anemia
case
point
malaria
coinfect
consid
signific
risk
sever
anemia
children
live
malariaendem
region
studi
examin
interrelationship
malaria
infect
anemia
howev
produc
inconsist
result
retrospect
studi
papua
new
guinea
png
children
year
age
yearold
seroposit
infect
significantli
associ
sever
anemia
even
absenc
risk
factor
includ
malaria
similar
result
obtain
children
republ
niger
howev
studi
malawi
kenya
show
evid
infect
contribut
anemia
children
seropreval
rel
low
time
studi
perform
png
niger
chloroquin
cq
use
firstlin
treatment
malaria
countri
addit
serosurvey
perform
eritrea
time
cq
firstlin
agent
also
reveal
unusu
high
seropreval
contrast
cq
discontinu
malawi
resist
local
strain
plasmodium
falciparum
use
declin
kenya
seropreval
studi
conduct
although
cq
addit
antimalari
efficaci
broad
antivir
activ
also
enhanc
semliki
forest
viru
sfv
encephalomyocard
viru
emcv
infect
mice
epsteinbarr
viru
ebv
express
latter
effect
thought
play
role
higher
incid
ebvinduc
burkitt
lymphoma
malariaendem
area
cq
common
use
hypothes
therefor
geoepidemiolog
differ
seropreval
pathogen
potenti
result
cqassoci
enhanc
replic
test
hypothesi
examin
effect
cq
commonlyus
antimalari
drug
replic
three
differ
cultur
cell
line
addit
examin
relationship
infect
use
drug
sampl
children
png
hospit
sever
anemia
result
provid
evid
cq
aq
aggrav
anemia
promot
replic
patient
particip
prospect
observ
genet
studi
sever
pediatr
infect
http
wwwmalariagennethom
written
inform
consent
obtain
parentguardian
ethic
approv
studi
obtain
png
institut
medic
research
institut
review
board
medic
research
advisori
committe
png
depart
health
studi
conduct
accord
helsinki
declar
plasma
sampl
obtain
donat
center
genotyp
csl
behr
ag
charlott
nc
concentr
ultracentrifug
wv
sucros
cell
cultur
rpmi
fc
uml
recombin
human
erythropoietin
epo
janssencilag
midrand
south
africa
cell
cultur
mem
supplement
fc
bone
marrow
mononuclear
cell
bmmc
obtain
frozen
stock
stemcel
technolog
vancouv
bc
canada
cultur
imdm
fc
uml
epo
cell
incub
atmospher
drug
purchas
sigma
st
loui
miss
chloroquin
diphosph
cq
primaquin
diphosph
pq
amodiaquin
dihydrochlorid
dihydr
aq
dissolv
water
piperaquin
ppq
lactic
acid
mefloquin
hydrochlorid
mq
dmso
lumefantrin
lft
dimethylformamid
artesun
pyrimethamin
pm
ethanol
final
drug
concentr
rang
use
infect
assay
pq
lft
aq
pm
mq
ppq
cq
highest
concentr
drug
exceed
total
cultur
volum
infect
assess
two
differ
cell
line
name
megakaryoblast
leukemia
cell
human
hepatocellular
liver
carcinoma
cell
line
primari
bone
marrow
mononuclear
cell
bmmc
cell
suscept
cell
line
infect
although
viral
rna
dna
protein
detect
cell
viral
replic
restrict
level
normal
allow
product
viru
progeni
cell
line
chosen
allow
viru
bind
probabl
intern
nonpermiss
infect
bmmc
shown
support
infect
although
minor
subset
cell
permiss
bone
marrow
mononuclear
cell
bmmc
infect
dnacontain
particl
per
cell
bmmc
correspond
moi
approxim
bmmc
presenc
predetermin
concentr
select
drug
viral
rna
dna
analysi
cell
collect
differ
postinfect
time
indic
figur
legend
total
poli
mrna
isol
viral
mrna
quantifi
previous
describ
total
dna
extract
viral
dna
quantifi
use
establish
method
cell
infect
specifi
presenc
cq
increas
postinfect
time
see
figur
cell
lyse
protein
load
buffer
total
protein
resolv
sodium
dodecyl
sulfat
sd
polyacrylamid
gel
electrophoresi
page
transfer
pvdf
membran
blot
probe
mous
antibodi
structur
protein
dilut
us
biolog
swampscott
follow
horseradish
peroxidaseconjug
secondari
antibodi
dilut
viral
structur
protein
visual
chemiluminesc
system
pierc
rockford
il
addit
viral
protein
express
examin
immunofluoresc
previous
describ
cell
infect
viral
particl
per
cell
moi
h
cell
wash
time
pb
remov
unbound
viru
incub
presenc
absenc
antimalari
increas
postintern
time
h
cell
wash
time
pb
amount
intact
viral
dna
quantifi
specifi
studi
children
year
age
sever
anemia
hemoglobin
gl
communitybas
age
sexmatch
healthi
control
children
hemoglobin
gl
sever
anemia
repres
subset
children
admit
modilon
hospit
madang
provinc
north
coast
png
sever
ill
period
studi
modilon
hospit
referr
hospit
provinci
facil
abl
manag
sever
ill
children
children
given
treatment
recommend
png
nation
treatment
guidelin
includ
intramuscular
artemeth
malaria
infect
healthi
control
recruit
villag
patient
slideneg
malaria
well
hemoglobin
concentr
angelholm
sweden
present
plasma
assay
igm
eia
kit
biotrin
intern
sever
anemia
viral
dna
use
two
specif
oligonucleotid
primer
test
viremia
start
declin
specif
igm
produc
around
day
inocul
virusinduc
marrow
suppress
last
anoth
week
thu
although
simultan
detect
igm
dna
strongli
indic
acut
infect
want
exclud
children
evid
recent
resolv
infect
contributor
sever
anemia
igm
pcr
posit
plasma
assay
chloroquin
amodiaquin
respect
activ
desethyl
metabolit
use
valid
high
perform
liquid
chromatographi
assay
assay
limit
quantit
analyt
cq
increas
product
gene
transcript
h
incub
cq
concentr
rang
rna
increas
figur
similarli
kinet
studi
presenc
cq
show
viral
dna
synthesi
rapid
extens
untreat
cell
figur
express
structur
viral
protein
extract
infect
cell
also
increas
presenc
cq
figur
viral
protein
express
detect
h
untreat
cell
h
cqtreat
cell
immunofluoresc
experi
show
presenc
cq
larger
number
cell
infect
fig
absenc
cq
minor
amount
viral
dna
synthesi
observ
start
h
postinfect
viral
rna
could
detect
confirm
poor
permiss
cell
line
infect
howev
presenc
increas
concentr
cq
viral
dna
synthesi
increas
progress
reach
cq
concentr
figur
kinet
studi
show
presenc
cq
viral
dna
detect
earlier
untreat
cell
figur
viral
rna
detect
cqtreat
cell
figur
presenc
cq
acceler
rna
synthesi
howev
cqtreat
cell
viral
rna
transcript
ceas
abruptli
follow
progress
degrad
resembl
apoptosi
figur
detect
phosphatidyl
v
complex
fluoresc
microscopi
confirm
infect
bmmc
enter
apoptot
pathway
data
shown
therefor
effect
cq
cultur
bmmc
could
evalu
stage
later
h
postinfect
apoptot
effect
observ
cell
line
concentr
data
shown
except
cqanalogu
aq
enhanc
infect
concentr
antimalari
drug
signific
effect
infect
figur
mild
inhibit
observ
presenc
mq
inhibit
infect
concentr
effect
also
observ
drug
ad
h
postinfect
data
shown
rais
possibl
infect
reduc
drugspecif
cytotox
enhanc
infect
cq
decreas
progress
increas
time
cq
ad
detect
effect
h
postinfect
figur
data
indic
cq
act
earli
infect
progress
time
intern
cell
wash
viral
dna
quantifi
untreat
cell
progress
degrad
incom
viral
dna
evid
howev
presenc
cq
aq
degrad
incom
particl
prevent
minim
figur
serolog
screen
reveal
healthi
control
children
sever
anemia
igm
posit
p
fisher
exact
test
igmneg
children
sever
anemia
posit
pcr
igmposit
children
also
pcr
posit
igm
andor
pcr
posit
children
sever
anemia
plasma
avail
assay
detect
metabolit
concentr
base
respect
pharmacokinet
profil
suggest
children
treat
either
cq
aq
within
previou
week
hemoglobin
concentr
igmpcr
statu
shown
figur
lowest
concentr
children
igm
pcr
posit
ie
acut
infect
children
similar
mean
age
vs
month
bodi
weight
kg
group
spleen
size
vs
cm
children
either
igm
pcr
posit
p
mannwhitney
u
test
percentag
malaria
similar
vs
p
fisher
exact
test
patient
igm
pcr
posit
indic
recent
necessarili
acut
infect
one
acut
earli
cours
use
associ
significantli
lower
admiss
hemoglobin
concentr
p
although
number
patient
treat
aq
small
restrict
children
igm
posit
pcr
neg
highest
hemoglobin
concentr
subgroup
suggest
consist
vitro
data
cq
greater
suppress
effect
bone
marrow
aq
patient
sever
anemia
common
lifethreaten
complic
malaria
children
live
endem
area
coinfect
identifi
major
factor
pathogenesi
signific
region
differ
seropreval
result
clinic
impact
despit
fact
infect
common
childhood
ill
sever
anemia
appear
parallel
local
use
cq
firstlin
treatment
malaria
hypothes
cq
promot
replic
consequ
contribut
indirectli
sever
anemia
although
profound
clinic
studi
would
necessari
present
result
provid
alreadi
strong
evid
hypothesi
apart
antimalari
effect
cq
wide
antivir
activ
one
import
mechan
action
virus
alkalin
endosom
vesicl
way
cq
activ
virus
requir
low
ph
step
cell
entri
flaviviru
retroviru
coronaviru
parvovirus
studi
date
also
depend
endosom
acidif
cell
entri
facilit
capsid
structur
transit
particular
extern
ntermin
region
requir
endosom
escap
nuclear
target
accordingli
cq
inhibit
parvoviru
infect
howev
previous
shown
uniqu
among
parvovirus
alreadi
extern
receptor
bind
thu
depend
low
endosom
ph
critic
conform
chang
also
uniqu
among
parvovirus
higher
sensit
acid
degrad
consequ
cqassoci
alkalin
endosom
vesicl
would
expect
minim
acid
degrad
incom
particl
data
confirm
intracellular
degrad
prevent
minim
presenc
cq
aq
howev
lysosomotrop
drug
ammonium
chlorid
bafilomycin
also
rais
endosom
ph
inhibitori
effect
infect
vitro
system
data
shown
therefor
mechan
underli
stabil
cq
aq
like
extend
beyond
phneutral
activ
destabil
endosomelysosom
membran
typic
observ
cqtreat
cell
way
cq
would
facilit
endosom
escap
reach
degrad
lysosom
compart
increas
number
particl
target
nuclei
replic
particular
import
sinc
nuclear
target
identifi
major
limit
factor
parvoviru
infect
plausibl
vitro
observ
explan
epidemiolog
data
depend
pharmacolog
properti
cq
especi
tissu
concentr
vitro
enhanc
infect
cq
achiev
concentr
well
achiev
plasma
therapeut
dose
children
typic
howev
replic
plasma
tissu
primarili
bone
marrow
cq
concentr
bone
marrow
substanti
higher
plasma
measur
approxim
anim
studi
could
reflect
part
concentr
drug
within
precursor
cell
observ
circul
erythrocyt
long
termin
elimin
halflif
cq
around
day
children
mean
condit
favor
viral
replic
bone
marrow
may
persist
sever
week
dose
mani
malariaendem
region
antimalari
therapi
given
empir
febril
children
without
blood
smear
confirm
iron
might
includ
fever
due
administr
frequent
cours
cq
may
mean
child
spend
long
period
year
risk
cqassoci
enhanc
viremia
consequ
anemia
aq
long
halflif
compound
like
cq
also
promot
replic
vitro
experi
drug
test
includ
primaquin
mefloquin
methanol
quinolin
influenc
infect
vitro
suggest
effect
specif
compound
viral
infect
sfv
emcv
ebv
enhanc
cq
antimalari
drug
abl
obtain
preliminari
human
data
consist
laboratori
find
unselect
png
children
particip
casecontrol
studi
sever
pediatr
infect
confirm
previou
report
seroposit
associ
sever
anemia
lowest
hemoglobin
concentr
children
acut
infect
ie
igm
pcr
posit
although
limit
number
evid
prior
especi
cq
use
exacerb
sever
anemia
apart
igm
pcrposit
case
presum
stage
maxim
viral
replic
consequ
bone
marrow
suppress
properli
design
epidemiolog
studi
larger
nonconveni
sampl
howev
need
confirm
find
although
cq
safe
inexpens
antimalari
drug
increas
emerg
resist
p
falciparum
p
vivax
seen
use
declin
throughout
tropic
data
suggest
preval
sever
malari
anemia
also
fall
result
howev
effect
vaccin
becom
avail
consid
prioriti
intervent
pediatr
seropreval
rate
high
caus
anemia
nutrit
defici
intestin
parasit
infect
present
artemisininbas
combin
therapi
act
current
whorecommend
firstlin
treatment
uncompl
malaria
data
suggest
pend
definit
vivo
data
includ
appropri
design
clinic
trial
drug
prefer
partner
artemisinin
deriv
contribut
sever
anemia
minim
